Sign In
Buy SGMO
$0.216
+0.0022 (+1.03%)
At Close: Jun 03, 2026
Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript
06:30pm, Thursday, 14'th May 2026
Sangamo Therapeutics, Inc. (SGMO) Q1 2026 Earnings Call Transcript
Sangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue Estimates
06:17pm, Thursday, 14'th May 2026
Sangamo Therapeutics (SGMO) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to a loss of $0.14 per share a year ago.
Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2026 Financial Results
04:01pm, Thursday, 14'th May 2026
Rolling submission of Biologics License Agreement (BLA) to U.S. Food and Drug Administration (FDA) seeking ST-920 approval is in progress. Six sites activated in Phase 1/2 STAND study evaluating ST-50
RICHMOND, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the American Society of Gene & Cell Therapy (ASGCT) has
Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market
08:05am, Wednesday, 29'th Apr 2026
RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that its common stock will transition from trading on The Na
Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript
06:22pm, Monday, 30'th Mar 2026
Sangamo Therapeutics, Inc. (SGMO) Q4 2025 Earnings Call Transcript
Sangamo Therapeutics Reports Recent Business Highlights And Fourth Quarter And Full Year 2025 Financial Results
04:01pm, Monday, 30'th Mar 2026
Announced in June, positive topline results from registrational STAAR study in Fabry disease, including positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across al
Sangamo Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
04:07am, Monday, 30'th Mar 2026
Sangamo Therapeutics will release Q4 earnings on March 30. Analysts predict a quarterly loss of 5 cents per share and revenue of $40.25 million.
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2025 Earnings Call
04:03pm, Thursday, 19'th Mar 2026
RICHMOND, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company today announced that the company has scheduled the release of its fourth quar
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
08:05am, Monday, 09'th Mar 2026
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally s
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium™ 2026
04:05pm, Tuesday, 03'rd Feb 2026
Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally s
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
09:10am, Tuesday, 03'rd Feb 2026
RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,
Sangamo Therapeutics Initiates Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
08:05am, Thursday, 18'th Dec 2025
STAAR study demonstrated positive mean annualized estimated glomerular filtration rate (eGFR) slope at 52-weeks across all dosed patients in the study, which U.S. Food and Drug Administration (FDA) ha
Sangamo Therapeutics Receives U.S. FDA Fast Track Designation for ST-503 for the Treatment of Small Fiber Neuropathy
08:05am, Tuesday, 02'nd Dec 2025
RICHMOND, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has granted
Sangamo Therapeutics Announces FDA Acceptance of BLA Rolling Submission Request for ST-920 in Fabry Disease
08:05am, Friday, 21'st Nov 2025
RICHMOND, Calif., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced that the U.S. Food and Drug Administration (FDA) has accepted
